(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
The Manual for Decent European Urban communities in 2024- Vote in favor of Your Number one kind of pie
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- Independence from the rat race for Recent college grads: Systems and Tips
- Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
